AstraZeneca, 760 Winter St, Waltham, MA 02451, US

Morphic Therapeutic Inc is a pioneering biopharmaceutical company based in Waltham, MA, specializing in the development of oral integrin medicines. Leveraging their extensive expertise in integrin biology, they aim to transform treatment paradigms for patients across multiple therapeutic areas, including autoimmune diseases, fibrosis diseases, and cancer. Their lead candidate, MORF-057, is a highly specific inhibitor of 4 7 currently in Phase 2 for inflammatory bowel disease (IBD). With a pipeline that encompasses both novel and highly validated targets, Morphic Therapeutic is committed to drugging integrins through small molecules to address unmet medical needs. They have also established a research partnership with Janssen to discover inhibitors of undisclosed integrin targets, expanding their knowledge of integrin biology into modalities beyond small molecules. Additionally, Morphic is actively developing small molecule inhibitors for the treatment of pulmonary arterial hypertension (PAH), solid tumors, and other indications, utilizing their MInT Platform to create therapeutically relevant compounds with enhanced attributes.Generated from the website